Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx (Nasdaq: LUNG) reported financial results for Q1 2024, achieving a 30% year-over-year revenue growth, recording $18.9 million in worldwide revenue, with $12.9 million in U.S. revenue. The company realized a gross margin of 75% and treated the first patient in significant clinical trials. Pulmonx appointed new executives to drive growth and expects revenue for 2024 to be in the range of $81 million to $84 million.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
